UNSPSC 51382102: Carprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H12ClNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FFL0D546HO, chemically known as 9h-carbazole-2-acetic acid, 6-chloro-alpha-methyl- but generally known as carprofen, which bears US NIH Compound Identifier 2581. European Medicines Agency schedules Carprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06144MIG.

UNSPSC 51382102 Carprofen is a Commodity code that in recent state and local procurement activity captures the supply of pharmaceutical products and related health-support systems to public health agencies and multistate cooperative purchasing consortia. The code shows minimal direct sourcing specifically for carprofen; instead, recent opportunities reflect state and local demand for broader pharmaceutical supply arrangements, naloxone emergency-response systems, and generic multistate pharmacy procurement frameworks. Issuing bodies span state health and human services departments, county public-health offices, and multistate cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, and the Texas Health and Human Services Commission represent state-level repeat procurement activity, while Seminole County, Florida demonstrates county-level engagement.

Geographic activity concentrates in Texas, Minnesota, and Florida, with multistate cooperative purchasing extending across numerous additional jurisdictions through MMCAP's participating state network. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026; due July 26, 2026) soliciting 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive bidding; the Texas HHS Commission's Request for Information HHS0017013 (posted April 3, 2026; response due April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels; and MMCAP's RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) establishing multi-award contracts for generic pharmaceuticals and OTC products across Minnesota, Oregon, and participating jurisdictions through three authorized wholesalers, with pricing weighted 75 percent and compliance with cGMP and Drug Supply Chain Security Act requirements mandatory. Contract terms typically range from two to three years with renewal options, and vendors must meet insurance, E-Verify, and federal environmental compliance standards.